News | News By Subject | News by Disease News By Date | Search News

Diabetic nephropathy/sclerosis News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Pfizer Inc. (PFE) Reports Top-Line Results From Two Placebo-Controlled Studies With Lyrica     8/13/2014
Immunosyn Corporation (IMYN.OB) Announces the Successful Completion of First Phase 'Proof of Concept Trial' in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019     1/18/2008
Schwarz Pharma Reveals Positive Phase III Data On Neuropathic Pain Drug Lacosamide; Shares Soar     3/31/2006
Keryx Biopharmaceuticals (KERX) Finalizes Special Protocol Assessment (SPA) Agreement With FDA For KRX-101 Phase 3 And Phase 4 Clinical Trials     3/16/2005
AVANIR Pharmaceuticals (AVN) Acquires Additional Rights To IriSys, Inc.'s Neurodex Technology; $1,925,000 In Cash; 2,000,000 Shares Of AVANIR Class A common stock     3/9/2005
AVANIR Pharmaceuticals (AVN) Receives Special Protocol Assessment For Neurodex Neuropathic Pain Clinical Trial; Phase III Trial To Begin First Half Of 2005     1/12/2005
FDA And Eli Lilly and Company (LLY) Approves Antidepressant Cymbalta(R) For Treatment Of Pain Caused By Diabetic Peripheral Neuropathy, Which Affects Up To 5 Million Americans     9/7/2004
Keryx Biopharmaceuticals (KERX) Announces $32 Million Private Equity Financing With Institutional Investors     2/13/2004

News from Around the Web

Press Releases
FDA Clears Genentech (RHHBY)'s Lucentis For All Forms Of Diabetic Retinopathy     4/18/2017
BioNevia And Neuromax Announce Completion Of Enrollment In Phase IIb Clinical Trial Of BNV-222     5/16/2016
Maxwell Biotech Venture Fund's Portfolio Company Neuromax Announce Completion Of Enrollment In Phase 2b Clinical Trial Of BNV-222     5/13/2016
Depomed (DEPO) To Present At Four Investor Events In December     11/24/2015
BioDelivery Sciences International (BDSI) Provides Corporate Update And Reports Second Quarter 2015 Financial Results     8/10/2015
Pharmaleads Announces The Inclusion Of The First Patient In Phase IIa Study Of Oral PL37 For Pain In Diabetic Neuropathy     4/22/2015
Servier Initiates Phase 2 Study Of Gevokizumab In Patients With Diabetic Nephropathy     4/1/2015
BioDelivery Sciences International (BDSI) Announces Completion Of Patient Enrollment In Its Initial Phase 3 Trial Of Clonidine Topical Gel For Painful Diabetic Neuropathy     6/26/2014
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference     6/2/2014
SK Bio-Pharmaceuticals to Initiate Phase 2 Trials in US     2/22/2012
Cardium Therapeutics, Inc. (CDTP.OB) Advancing Excellarate to Phase 2b Clinical Study     5/1/2007
Depomed, Inc. (DEPO) Obtains Exclusive License To Gabapentin Use In Hot Flashes     10/18/2006
Depomed, Inc. (DEPO) Completes Enrollment In Phase II Clinical Trial in Diabetic Peripheral Neuropathy With Gabapentin GR     10/5/2006
Sangamo BioSciences, Inc. (SGMO) Announces Plans For Phase 2 Clinical Trial Of ZFP Therapeutic In Diabetic Neuropathy At JPMorgan Healthcare Conference     1/12/2006
Pre-Clinical Toxicity Studies Show Quigley Pharma Inc.'s (QGLY) Diabetic Neuropathy Formulation QR-333 Is Safe For Topical Application     10/18/2005